ストックスクリーナーアプリを入手
1.41
2.08%
-0.03
プレマーケット:
1.38
-0.03
-2.13%
前日終値:
$1.44
開ける：
$1.45
24時間の取引高:
60,961
Relative Volume:
0.79
時価総額：
$13.88M
収益：
-
当期純損益:
$-19.44M
株価収益率:
-0.5304
EPS:
-2.6585
ネットキャッシュフロー:
$-12.71M
1週間 パフォーマンス:
+2.92%
1か月 パフォーマンス:
-18.02%
6か月 パフォーマンス:
-40.00%
1年 パフォーマンス:
-68.89%
1日の値動き範囲:
$1.41
$1.50
1週間の範囲:
$1.3501
$1.51
52週間の値動き範囲:
$1.17
$5.817
In 8 Bio Inc Stock (INAB) Company Profile
Compare INAB vs VRTX, REGN, ARGX, ALNY, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
1.41 | 13.88M | 0 | -19.44M | -12.71M | -2.6585 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 110.47B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.67B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.53B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 43.81B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.36B | 606.42M | -1.28B | -997.58M | -6.403 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-03-18 | 開始されました | Laidlaw | Buy |
| 2022-08-30 | 開始されました | H.C. Wainwright | Buy |
In 8 Bio Inc (INAB) 最新ニュース
8 Most Oversold Penny Stocks to Buy Right Now - Insider Monkey
Adaptin Bio shares approved for OTCQB quotation under ticker APTN; trading to begin in 6-8 weeks - TradingView
Adaptin Bio (APTN) wins OTCQB quotation and advances APTN-101 program - Stock Titan
ImmunityBio (NASDAQ: IBRX) outlines response to FDA ad concerns - Stock Titan
Climb Bio, Inc. 8-K Filing Details: Company Information, Address, and Stock Exchange Listing (April 2026) - Minichart
Entera Bio (NASDAQ: ENTX) completes private placement with BVF funds - Stock Titan
Climb Bio (CLYM) consolidates CFO and principal accounting officer roles - Stock Titan
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Instil Bio (TIL) replaces Deloitte with RSM as independent auditor - Stock Titan
[144] Annovis Bio, Inc. SEC Filing - Stock Titan
Palisade Bio (NASDAQ: PALI) sells 1.54M shares to Iterative Health affiliate - Stock Titan
GOSS SEC FilingsGossamer Bio 10-K, 10-Q, 8-K Forms - Stock Titan
KALA SEC FilingsKala Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
APTN SEC FilingsAdaptin Bio 10-K, 10-Q, 8-K Forms - Stock Titan
LeonaBio (NASDAQ: ATHA) expands Sermonix deal disclosure and ELAINE-3 trial spend - Stock Titan
ImmunityBio (NASDAQ: IBRX) adds $75M non-dilutive cash and converts $25M debt - stocktitan.net
Passage Bio Inc Stock: Gene Therapy Innovator Faces Clinical and Funding Hurdles in Competitive Biot - AD HOC NEWS
Vor Bio (Nasdaq: VOR) secures $75M private placement to fund telitacicept - Stock Titan
[8-K] Instil Bio, Inc. Reports Material Event - Stock Titan
Tela Bio targets at least 8% revenue growth in 2026 while advancing commercial transformation - MSN
LeonaBio (NASDAQ: LONA) boosts cash to fund Phase 3 breast cancer drug - stocktitan.net
Upstream Bio (NASDAQ: UPB) establishes $150M at-the-market stock program - Stock Titan
bioAffinity Technologies (BIAF) shares March 2026 investor presentation materials - Stock Titan
Upstream Bio (NASDAQ: UPB) deepens 2025 loss while推进 Phase 3 verekitug strategy - Stock Titan
Tevogen Bio Holdings Inc. Files Form 8-K on NASDAQ: Company Details and Key Information for March 2026 - Minichart
Annovis Bio, Inc. Files Form 8-K with NYSE Listing and Corporate Information for March 23, 2026 - Minichart
Annovis Bio's Mark Guerin departs as CFO; Maria Maccecchini to serve as Acting CFO - TradingView
CFO departs Annovis Bio (ANVS) as CEO Maria Maccecchini takes acting finance role - Stock Titan
Tevogen Bio (TVGN) restores Nasdaq bid-price compliance after 1-for-50 reverse split - Stock Titan
bioAffinity Technologies (BIAF) plans CyPath Lung webinar showcasing real-world clinical use - Stock Titan
TELA Sees Growth with FY26 Revenue Projected to Rise at Least 8% - GuruFocus
TELA Bio (NASDAQ: TELA) lifts 2025 sales 16% but posts $38.8M loss - Stock Titan
Medical device maker secures up to $70M after 18% sales gain - Stock Titan
INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th. - The Manila Times
INmune Bio will discuss 2025 results and corporate update March 30 - stocktitan.net
PALI SEC FilingsPalisade Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Cabaletta Bio (NASDAQ: CABA) details 2025 results and advances rese-cel trials - Stock Titan
ANVS SEC FilingsAnnovis Bio Inc 10-K, 10-Q, 8-K Forms - stocktitan.net
UPB SEC FilingsUpStream Bio Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Palisade Bio Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
TELA Bio Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
TELA Bio (TELA) hit with Nasdaq $1 bid-price deficiency, faces delisting risk - Stock Titan
NUVB SEC FilingsNuvation Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
[8-K] BIO-PATH HOLDINGS, INC. Reports Material Event | BPTH SEC FilingForm 8-K - Stock Titan
LeonaBio (ATHA) wins approval for 2026 equity plan and major share increase - Stock Titan
[EFFECT] Gossamer Bio, Inc. SEC Filing - Stock Titan
Passage BIO (PASG) CEO receives 58,000-share stock option grant - Stock Titan
[144] KALA BIO, Inc. SEC Filing - Stock Titan
Gossamer Bio (NASDAQ: GOSS) 2025 loss widens as seralutinib Phase 3 misses goal - Stock Titan
Phase 3 trial push deepens 2025 loss at Annovis Bio (NYSE: ANVS) - Stock Titan
Kyntra Bio (Nasdaq: KYNB) unveils 2025 results, FG-3246 and roxadustat plans - Stock Titan
In 8 Bio Inc (INAB) 財務データ
収益
当期純利益
現金流量
EPS
0.87%
0.11%
大文字化:
|
ボリューム (24 時間):